RNAi-mediated knockdown of HMG CoA reductase enhances gene expression from physiologically regulated low-density lipoprotein receptor therapeutic vectors in vivo

Gene Therapy

Volumn 19, Issue 4, 2012, Pages 463-467

  Hibbitt, O ^a   Agkatsev, S ^a   Owen, C ^a   Cioroch, M ^a   Seymour, L ^a   Channon, K ^b   Wade Martins, R ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

cholesterol; familial hypercholesterolaemia; hydrodynamic injection; live imaging; microRNA

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LOW DENSITY LIPOPROTEIN RECEPTOR; MICRORNA; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; FAMILIAL DISEASE; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; GENE THERAPY; GENE VECTOR; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA INTERFERENCE;

ANIMALS; CELL LINE; CHOLESTEROL, LDL; FEMALE; GENE KNOCKDOWN TECHNIQUES; GENE THERAPY; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYPERLIPOPROTEINEMIA TYPE II; LIVER; MICE; MICRORNAS; RECEPTORS, LDL; RNA INTERFERENCE;

MUS;

EID: 84859614946     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2011.103     Document Type: Article

References (25)

1. Chowdhury JR, Grossman M, Gupta S, Chowdhury NR, Baker Jr JR, Wilson JM. Long-term improvement of hypercholesterolemia after ex vivo gene therapy in LDLR-deficient rabbits. Science 1991; 254: 1802-1805. (Pubitemid 21917532)
2. Grossman M, Rader DJ, Muller DW, Kolansky DM, Kozarsky K, Clark III BJ et al. A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nat Med 1995; 1: 1148-1154.
3. Miyanohara A, Sharkey MF, Witztum JL, Steinberg D, Friedmann T. Efficient expression of retroviral vector-transduced human low density lipoprotein (LDL) receptor in LDL receptor-deficient rabbit fibroblasts in vitro. Proc Natl Acad Sci USA 1988; 85: 6538-6542.
4. Wilson JM, Johnston DE, Jefferson DM, Mulligan RC. Correction of the genetic defect in hepatocytes from the Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci USA 1988; 85: 4421-4425.
5. Kankkonen HM, Vahakangas E, Marr RA, Pakkanen T, Laurema A, Leppanen P et al. Long-term lowering of plasma cholesterol levels in LDL-receptor-deficient WHHL rabbits by gene therapy. Mol Ther 2004; 9: 548-556. (Pubitemid 38578805)
6. Ishibashi S, Brown MS, Goldstein JL, Gerard RD, Hammer RE, Herz J. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest 1993; 92: 883-893. (Pubitemid 23262411)
7. Kozarsky KF, Jooss K, Donahee M, Strauss III JF, Wilson JM. Effective treatment of familial hypercholesterolaemia in the mouse model using adenovirus-mediated transfer of the VLDL receptor gene. Nat Genet 1996; 13: 54-62. (Pubitemid 26139294)
8. Kozarsky KF, McKinley DR, Austin LL, Raper SE, Stratford-Perricaudet LD, Wilson JM. In vivo correction of low density lipoprotein receptor deficiency in the Watanabe heritable hyperlipidemic rabbit with recombinant adenoviruses. J Biol Chem 1994; 269: 13695-13702. (Pubitemid 24206152)
9. Li J, Fang B, Eisensmith RC, Li XH, Nasonkin I, Lin-Lee YC et al. In vivo gene therapy for hyperlipidemia: phenotypic correction in Watanabe rabbits by hepatic delivery of the rabbit LDL receptor gene. J Clin Invest 1995; 95: 768-773.
10. Nomura S, Merched A, Nour E, Dieker C, Oka K, Chan L. Low-density lipoprotein receptor gene therapy using helper-dependent adenovirus produces long-term protection against atherosclerosis in a mouse model of familial hypercholesterolemia. Gene Therapy 2004; 11: 1540-1548. (Pubitemid 39359462)
11. Jacobs F, Van Craeyveld E, Feng Y, Snoeys J, De Geest B. Adenoviral low density lipoprotein receptor attenuates progression of atherosclerosis and decreases tissue cholesterol levels in a murine model of familial hypercholesterolemia. Atherosclerosis 2008; 201: 289-297.
12. Van Craeyveld E, Gordts SC, Nefyodova E, Jacobs F, De Geest B. Regression and stabilization of advanced murine atherosclerotic lesions: a comparison of LDL lowering and HDL raising gene transfer strategies. J Mol Med 2011; 89: 555-567.
13. Lebherz C, Gao G, Louboutin JP, Millar J, Rader D, Wilson JM. Gene therapy with novel adeno-associated virus vectors substantially diminishes atherosclerosis in a murine model of familial hypercholesterolemia. J Gene Med 2004; 6: 663-672. (Pubitemid 40228082)
14. Kassim SH, Li H, Vandenberghe LH, Hinderer C, Bell P, Marchadier D et al. Gene therapy in a humanized mouse model of familial hypercholesterolemia leads to marked regression of atherosclerosis. PLoS One 2010; 5: e13424.
15. Cichon G, Willnow T, Herwig S, Uckert W, Loser P, Schmidt HH et al. Non-physiological overexpression of the low density lipoprotein receptor (LDLr) gene in the liver induces pathological intracellular lipid and cholesterol storage. J Gene Med 2004; 6: 166-175. (Pubitemid 40228035)
16. Heeren J, Steinwaerder DS, Schnieders F, Cichon G, Strauss M, Beisiegel U. Non-physiological overexpression of low-density lipoprotein receptors causes pathological intracellular lipid accumulation and the formation of cholesterol and cholesteryl ester crystals in vitro. J Mol Med 1999; 77: 735-743.
17. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002; 109: 1125-1131. (Pubitemid 34496588)
18. Briggs MR, Yokoyama C, Wang X, Brown MS, Goldstein JL. Nuclear protein that binds sterol regulatory element of low density lipoprotein receptor promoter. I. Identification of the protein and delineation of its target nucleotide sequence. J Biol Chem 1993; 268: 14490-14496. (Pubitemid 23195580)
19. Sudhof TC, Russell DW, Brown MS, Goldstein JL. 42 bp element from LDL receptor gene confers end-product repression by sterols when inserted into viral TK promoter. Cell 1987; 48: 1061-1069.
20. Hibbitt OC, McNeil E, Lufino MM, Seymour L, Channon K, Wade-Martins R. Long-term physiologically regulated expression of the low-density lipoprotein receptor in vivo using genomic DNA mini-gene constructs. Mol Ther 2010; 18: 317-326.
21. Boudreau RL, Martins I, Davidson BL. Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo. Mol Ther 2009; 17: 169-175.
22. Fountaine TM, Venda LL, Warrick N, Christian HC, Brundin P, Channon KM et al. The effect of alpha-synuclein knockdown on MPP+ toxicity in models of human neurons. Eur J Neurosci 2008; 28: 2459-2473.
23. Fountaine TM, Wade-Martins R. RNA interference-mediated knockdown of alphasynuclein protects human dopaminergic neuroblastoma cells from MPP(+) toxicity and reduces dopamine transport. J Neurosci Res 2007; 85: 351-363. (Pubitemid 46219303)
24. Lufino MM, Manservigi R, Wade-Martins R. An S/MAR-based infectious episomal genomic DNA expression vector provides long-term regulated functional complementation of LDLR deficiency. Nucleic Acids Res 2007; 35: e98.
25. Hibbitt OC, Harbottle RP, Waddington SN, Bursill CA, Coutelle C, Channon KM et al. Delivery and long-term expression of a 135 kb LDLR genomic DNA locus in vivo by hydrodynamic tail vein injection. J Gene Med 2007; 9: 488-497. (Pubitemid 47007415)